Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nevertheless, the future pushes on....
https://abcnews.go.com/GMA/Wellness/breast-cancer-vaccine-now-early-clinical-trials/story?id=105550075
The companies plan to continue expansion of the comprehensive clinical development program for V940 (mRNA-4157) to additional tumor types.
Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer
As lung cancer is the leading cause of cancer death worldwide, there is a need for continued scientific advancements to help fight this disease at earlier stages when patients have the best chance for better outcomes," said Dr. Marjorie Green, senior vice president and head of late-stage oncology, global clinical development, Merck Research Laboratories. "By combining KEYTRUDA with V940 (mRNA-4157), a promising new modality, we are researching innovative new approaches for earlier stage non-small cell lung cancer.
https://finance.yahoo.com/news/merck-moderna-initiate-interpath-002-114500239.html
There's no single cause of breast cancer.....
An end to breast cancer? California company develops groundbreaking vaccine with promising future
https://www.cbsnews.com/sacramento/news/an-end-to-breast-cancer-norcal-company-develops-groundbreaking-vaccine-with-promising-future/
Michelle Cleave and the Triple Negative Breast Cancer Vaccine Clinical Trial
https://interludecancerstories.com/2023/12/01/154-michele-cleave-and-the-triple-negative-breast-cancer-vaccine-clinical-trial/
another monster: https://www.graydc.com/video/2023/11/16/lnl-breast-cancer-vaccine-developments/
I was the first woman in the world to get breast cancer jab – it means I’ll see my kids grow up
Scientists reveal how they hope the jab could be used to wipe out the disease altogether.
The vaccine has been in development for the past 20 years, off the back of Dr Vincent Tuohy’s research at the Cleveland Clinic.
https://www.thesun.co.uk/health/24498500/first-woman-in-world-get-breast-cancer-jab-health/?utm_source=twitter&utm_medium=social&utm_campaign=sharebarweb
Company expects 2023 revenues of at least $6 billion
Cash, cash equivalents and investments were $12.8 billion as of September 30, 2023
Company anticipates 2024 revenue of approximately $4 billion and return to growth in 2025
Moderna expects to break even in 2026 through product launches and disciplined investments
Enjoy your trip$$$$$$
Regulators should decide on its closest-to-market candidate -- a respiratory syncytial virus (RSV) vaccine -- early next year.
Moderna aims to launch 15 new products over the coming five years, the company forecasts revenue of as much as $30 billion a few years following the launches.
bad news: Chinese take antibiotics for everything.
Chinese Hospitals Are Housing Another Deadly Outbreak
Authorities are covering up the spread of antibiotic-resistant pneumonia.
Now, Chinese doctors are once again being silenced and not communicating with their counterparts abroad, which suggests another potentially dangerous cover-up may be underway.
We don’t know exactly what is happening, but we can offer some informed guesses.
https://foreignpolicy.com/2023/11/28/chinese-hospitals-pandemic-outbreak-pneumonia/#:~:text=The%20World%20Health%20Organization%20(WHO,pneumonia%20or%20similar%20severe%20ailments.
SHANGHAI, Nov 28 (Reuters) - U.S. vaccine maker Moderna began construction of its first facility in China this month to manufacture mRNA medicines, the company said on Tuesday.
Moderna's COVID-19 vaccine has yet to be approved in China, but the company said in July it had signed a deal with the city government of China's financial hub Shanghai to work towards opportunities for it to research, develop and manufacture mRNA medicines in the country.
The facility in Shanghai would manufacture medicines for the domestic population, the world's second largest after India, a spokesperson for Moderna told Reuters.
"Our focus in China is on strengthening health security by targeting unmet needs and contributing to the ecosystem of medical solutions available to patients in China," it said in an emailed statement.
It did not say what it planned to make at the facility and when production might start.
The Company provided an update that most of the work has been completed on the key section of the MAA that remained to be done at the time of the prior update, as well as on required supporting documents, the majority of which have been delivered to the publisher/QC team. That team is now under way on this final stage of their work.
As described in the Company's prior update, it is anticipated that the publisher/QC team will need several weeks to complete their work on both the last portion of the MAA package and the integrated whole. Their work is independent of the Company.
-The next big advance in cancer treatment could be a vaccine- it's written on the wall
https://apnews.com/article/cancer-vaccines-research-immune-system-c35c8b3003fb75c1a848715a4b4f097f
5 Cancer Vaccines to Watch in 2024
https://www.biospace.com/article/5-cancer-vaccines-to-watch-in-2024/?keywords=pancreatic+cancer+phase+3
Cash runway extended through multiple data readouts and into Q1 of calendar 2025
MDNA11 is generally well tolerated and continues to demonstrate encouraging single-agent activity from Phase 1 portion of the ABILITY-1 Study including 100% and 70% reduction of target lesions in pancreatic and melanoma cancer patients, respectively
https://ir.medicenna.com/news-releases/news-release-details/medicenna-therapeutics-reports-second-quarter-fiscal-2024
Demand for RSV shot is so high, CDC is recommending it only for the most vulnerable
https://www.cbsnews.com/news/rsv-beyfortus-antibody-shot-demand-supply-respiratory-syncytial-virus/
Carisma's CEO discusses their Moderna-partnered CAR-M preclinical late breaker at #SITC23
https://www.biotechtv.com/post/carisma-therapeutics-november-3-2023
By the end of 2024, there's a good chance Spikevax won't be Moderna's only source of recurring revenue
Moderna expects an approval decision regarding its RSV vaccine candidate in April of 2024.
Moderna's RSV vaccine candidate, tentatively named mRNA-1354, reduced patients' risk of developing two or more RSV symptoms by 83.7% compared to a placebo. Moderna can argue that results for its candidate are best in class
ROLLING WHEEL
Moderna's potential RSV product could be successful since it would be the only one on the market available in a pre-filled syringe, making it very easy to administer.....
Moderna has also predicted that the 15 planned launches could bring in as much as $30 billion in sales in the coming years. And the company says its current balance sheet is strong enough to fund its plans, so it won't need to raise capital by selling shares.
Stéphane Bancel suggests Moderna could be open to out-licensing if sales struggle
https://www.fiercebiotech.com/biotech/modernas-bancel-suggests-potential-partnerships-depending-future-sales
it's sales time....Now$$$$$$ bright future
reported its third-quarter net loss was $3.63 billion, compared to the prior year’s net income of $1.04 billion. The drop in revenue resulted in a loss per share of $9.53, compared to earnings per share of $2.53 a year ago. Additionally, the company decreased product sales forecast from $8 billion to $6 billion.
Cash, Cash Equivalents and Investments: Cash, cash equivalents and investments were $12.8 billion as of September 30, 2023, down from $14.6 billion as of June 30, 2023, driven by the operating loss in the quarter.
Third quarter 2023 revenues of $1.8 billion; Company expects 2023 revenues of at least $6 billion
Spikevax U.S. market share to date increased to 45% from 36% in 2022
Company anticipates 2024 revenue of approximately $4 billion and return to growth in 2025
Company has significantly improved future cost of sales by resizing its manufacturing capacity, contributing to a third quarter net loss of $3.6 billion, primarily driven by mostly non-cash charges of $3.1 billion related to resizing and a tax valuation allowance
Company's late-stage pipeline has six Phase 3 programs
Company expects to break even in 2026 through product launches and disciplined investment
Research and Development (R&D) and Selling, General and Administrative (SG&A): The Company now expects full-year 2023 expenses of approximately $6.3 billion (previously $6 billion), with approximately $4.8 billion in R&D (previously $4.5 billion).
Clinical Updates
Moderna's mRNA platform is positioned to continue to deliver significant impact with our mRNA medicines. The Company is anticipating up to 15 launches in the next five years and provided a comprehensive overview of its pipeline and clinical programs at R&D Day in September. Moderna currently has therapeutics in development across four therapeutic areas, with a total of 43 development programs. Other notable updates are provided below.
https://investors.modernatx.com/news/news-details/2023/Moderna-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Updates--/default.aspx
How AI played an instrumental role in making mRNA vaccines
https://bigthink.com/health/ai-mrna-vaccines-moderna/
So let's see what happens - Unlike Pfizer, Moderna can meet 2023 COVID forecast, analysts say
https://finance.yahoo.com/news/1-unlike-pfizer-moderna-meet-100941842.html
life is a joke..... remember it always!
$RNA he is immortal....
no one is immortal..$MRNA winner
strength and courage that life is a passage......
Carisma Presents Pre-Clinical Proof of Concept for in vivo CAR-M using mRNA platform in collaboration with Moderna at SITC “In vivo CAR-M: Redirecting endogenous myeloid cells with mRNA for cancer immunotherapy” to be presented Friday, November 3, 2023, at 11:30 am PT
https://carismatx.com/carisma-presents-pre-clinical-proof-of-concept-for-in-vivo-car-m-using-mrna-platform-in-collaboration-with-moderna-at-sitc/
“The data presented at SITC is incredibly exciting as it demonstrates that we have the ability to make CAR-M directly in vivo with mRNA/LNP technology, leading to robust and targeted anti-tumor activity,” said Michael Klichinsky, PharmD, PhD, Co-Founder and Chief Scientific Officer at Carisma. “This off-the-shelf approach to treat cancer with engineered myeloid cells, developed in collaboration with Moderna, has the potential to transform the CAR field and be applied to numerous cancer targets and indications.”
“We are pleased to share data about the successful application of our mRNA platform to advance in vivo cell therapy,” said Lin Guey, PhD, Chief Scientific Officer of External Research Ventures at Moderna. “We look forward to the continuation of our pre-clinical work with Carisma and are optimistic that the joint scientific knowledge of both companies will accelerate the development of novel in vivo CAR-M therapies for patients.”
they live with blinders on------we are not all the same!
IH- it's early for the blue pill ...still runs like a Swiss watch
mark the date 2 November, rollercoaster!
R.I.P Twisted Anti-Vaxxers Rush to Blame Matthew Perry’s Death on Covid Vaccine
If that weren’t enough, anti-vaxxers edited Perry’s Wikipedia page to say, “It is unclear whether the drowning was due to complications from the COVID-19 vaccine.” (It has since been deleted.)
https://www.rollingstone.com/tv-movies/tv-movie-features/matthew-perry-death-blamed-on-covid-19-vaccine-by-anti-vaxxers-1234865224/
Vaccines Offer Surprising Protection Against Alzheimer’s- the anti-vaccine community is not going to like this one
https://www.forbes.com/sites/stevensalzberg/2023/10/30/vaccines-offer-surprising-protection-against-alzheimers/
Moderna to Report Third Quarter 2023 Financial Results on Thursday, November 2, 2023
this company isn't likely to depend on the vaccine for very long. Moderna has several candidates across treatment areas in late-stage development. And the company recently said it aims to launch as many as 15 products over the coming five years.
If Moderna succeeds, this could be big, catapulting the company to annual revenue of as much as $30 billion a few years after launch. These potential products span the areas of oncology, rare diseases, and, of course, respiratory diseases such as the coronavirus. The closest to market include a vaccine candidate for respiratory syncytial virus and a combination shot to prevent coronavirus and flu. They could launch in 2024 and 2025